Publications by authors named "Megan E Aanstoos"

2 Publications

  • Page 1 of 1

Do Mesenchymal Stromal Cells Influence Microscopic Residual or Metastatic Osteosarcoma in a Murine Model?

Clin Orthop Relat Res 2016 Mar;474(3):707-15

Department of Clinical Sciences and School of Biomedical Engineering, Colorado State University, 300 W Drake Road, Fort Collins, CO, 80525, USA.

Background: Mesenchymal stromal cells (MSCs) have been shown in rodent models to promote primary and pulmonary metastatic sarcoma growth when injected in the presence of gross tumor. In theory, this would limit their use in a clinical setting after limb salvage treatment for osteosarcoma. Although concerning, these models do not translate to the clinical setting wherein MSCs could be used after primary tumor resection to aid in bone healing and incorporation of tumor endoprostheses. If we can determine whether the use of MSCs in this setting is safe, it might improve our ability to augment bone healing in patients undergoing limb salvage.

Questions/purposes: The purpose of this study was to determine (1) whether MSCs promote pulmonary metastatic disease progression in a murine osteosarcoma model; and/or (2) whether they affect local disease recurrence in the presence of microscopic residual osteosarcoma.

Methods: An orthotopic model of luciferase-expressing osteosarcoma was developed. At 10 days, resection of the primary tumor was performed. One hundred fourteen female C3H mice were inoculated with DLM8-luc osteosarcoma in the proximal tibia. Ninety-four mice developed orthotopic osteosarcoma with luciferase expression. Mice with bioluminescent evidence of a primary tumor received either a microscopically "clean" amputation at a time when residual microscopic metastatic disease was present in the lungs (pulmonary metastasis group; n = 65) or a "dirty" amputation (local recurrence group; n = 29). Mice were randomized to receive intravenous MSCs, MSCs at the surgical site, or no MSCs. Mice were monitored for development and progression of pulmonary metastasis and local recurrence by bioluminescence imaging and daily measurements at the surgical site. The number of pulmonary nodules, time to first evidence of metastasis, and size of recurrent tumor were compared using Kruskal-Wallis, analysis of variance, Welch's, t-tests, or Mann-Whitney tests as appropriate for the specific data sets with p < 0.05 considered significant.

Results: Mice receiving intravenous MSCs had a faster time to first detection of pulmonary metastasis (2.93 ± 1.90 days) compared with mice with local injection of MSCs (6.94 ± 6.78 days) or no MSCs (5.93 ± 4.55 days) (p = 0.022). MSC treatment did not influence whether mice developed local recurrence (p = 0.749) or size of recurrent tumors (p = 0.221).

Conclusions: MSCs delivered to the surgical site did not promote local recurrence or size of recurrent tumors, but intravenous injection of MSCs did hasten onset of detection of pulmonary metastatic disease. Although local administration of MSCs into a surgical site does not appear to promote either pulmonary metastatic disease or local recurrence, large variation within groups and small numbers diminished statistical power such that a Type II error cannot be ruled out.

Clinical Relevance: If MSCs are to be used to augment bone healing in the postlimb salvage setting in patients with osteosarcoma, it will be important to understand their influence, if any, on pulmonary micrometastsis or residual microscopic local disease. Although murine models do not completely recapitulate the clinical scenario, these results suggest that intravenous delivery of MSCs may promote micrometastatic pulmonary disease. Local administration into a surgical wound, even in the presence of residual microscopic disease, may be safe, at least in this murine model, but further investigation is warranted before considering the use of MSCs for clinical use in patients with osteosarcoma.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11999-015-4362-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746149PMC
March 2016

Osteochondral lesions of the talus treated with fresh talar allografts.

Foot Ankle Int 2010 Apr;31(4):277-82

The Denver Clinic for Extremities at Risk, Limb Preservation, 1601 E. 19th Ave., Denver, CO 80218, USA.

Background: Osteochondral lesions of the talar dome (OLT) can be devastating injuries. Many of these problems occur in younger adult patients and can cause permanent joint pain and stiffness. Several treatment methods have been used to treat the symptomatic lesion, including arthroscopic debridement and microfracture, transfer of autologous osteoarticular tissue from the knee or talus (OATS), autologous chondrocyte implantation (ACI), frozen and fresh allograft transplantation.

Materials And Methods: Eighteen patients underwent fresh talar allograft transplantation with internal fixation for an OLT. Fresh talar allograft transplantation involved arthrotomy of the ankle, often with malleolar osteotomy, and replacement of the talar dome defect with fresh talar allograft tissue and internal fixation. Thirteen of the 18 patients returned for clinical and radiographic examination in addition to completing two validated questionnaires. The other five patients did not return for followup evaluation. The 13 patients who were seen in followup had an average age of 30 (range, 15 to 44) years with a mean followup of 48 months.

Results: There was a significant difference (p < 0.01) between the patients' preoperative and postoperative pain and activity abilities as measured with the Foot Function Index and AOFAS Ankle-Hindfoot questionnaires. Clinical examination and X-rays confirmed healing of the graft.

Conclusion: Based on these results, we conclude that this is a reasonable procedure for younger adult patients with focal osteochondral talar defects that cannot be corrected with curettage and microfracture.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3113/FAI.2010.0277DOI Listing
April 2010
-->